Head of Hong Kong’s new drug regulator pledges to build trust, push innovation
The head of Hong Kong’s new drug regulatory body has pledged to build a fully capable and globally trusted agency that will become a catalyst for medical innovation rather than merely acting as a “miniature version” of existing overseas models. Dr Li Zili, controller of the Hong Kong Centre for Medical Products Regulation (CMPR), said that while many other places in Asia, such as mainland China,…
Dr. Li Zili, the head of Hong Kong's new drug regulatory body, has pledged to build a globally trusted agency that will become a catalyst for medical innovation. He emphasized that Hong Kong has a distinctive competitive edge due to its "one country, two systems" governing principle and the strong pharmaceutical industry on the mainland.
Li, who has 30 years of drug development and regulatory experience, believes that the primary drug approval mechanism will ensure high quality, transparency, and predictability in the evaluation process.
Brief written by urgent.news from South China Morning Post's own syndicated text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
